Escape from flatland: Increasing saturation as an approach to improving clinical success

Journal of Medicinal Chemistry

Volumn 52, Issue 21, 2009, Pages 6752-6756

  Lovering, Frank ^a   Bikker, Jack ^b   Humblet, Christine ^a  

^a PFIZER INC   (United States)

^b WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON;

ARTICLE; CHEMICAL BOND; CHIRALITY; DRUG RESEARCH; MELTING POINT; MOLECULAR WEIGHT; MOLECULE; SOLUBILITY;

CARBON; DATABASES, FACTUAL; DRUG DESIGN; DRUG DISCOVERY; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSITION TEMPERATURE;

EID: 71049126548     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901241e     Document Type: Article

References (41)

1. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
2. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
3. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 2008, 51, 817-834.
4. Martin, Y. C. A bioavailability score. J. Med. Chem. 2005, 48, 3164-3170.
5. Pajouhesh, H.; Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005, 2, 541-553. (Pubitemid 41393264)
6. Arya, P.; Joseph, R.; Gan, Z.; Rakic, B. Exploring new chemical space by stereocontrolled diversity-oriented synthesis. Chem. Biol. 2005, 12, 163-180.
7. Morton, D.; Leach, S.; Cordier, C.; Warriner, S.; Nelson, A. Synthesis of natural-product-like molecules with over eighty distinct scaffolds. Angew. Chem., Int. Ed. 2009, 48, 104-109.
8. Burke, M. D.; Schreiber, S. L. A planning strategy for diversity-oriented synthesis. Angew. Chem., Int. Ed. 2004, 43, 46-58.
9. Schreiber, S. L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000, 287, 1964-1969. (Pubitemid 30158663)
10. Tan, D., S. Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat. Chem. Biol. 2005, 1, 74-84.
11. Bertz, S. H. The first general index of molecular complexity. J. Am. Chem. Soc. 1981, 103, 3599-3601.
12. Barone, R.; Chanon, M. A New and simple approach to chemical complexity. application to the synthesis of natural products. J. Chem. Inf. Comp. Sci. 2001, 41, 269-272.
13. Allu, T. K.; Oprea, T. I. Rapid evaluation of synthetic and molecular complexity for in silico chemistry. J. Chem. Inf. Mod. 2005, 45, 1237-1243.
14. Schuffenhauer, A.; Floersheim, P.; Acklin, P.; Jacoby, E. Similarity metrics for ligands reflecting the similarity of the target proteins. J. Chem. Inf. Comp. Sci. 2003, 43, 391-405.
15. Schuffenhauer, A.; Brown, N.; Selzer, P.; Ertl, P.; Jacoby, E. Relationships between molecular complexity, biological activity, and structural diversity. J. Chem. Inf. Mod. 2006, 46, 525-535.
16. Selzer, P.; Roth, H.-J.; Ertl, P.; Schuffenhauer, A. Complex molecules: do they add value? Curr. Opin. Chem. Biol. 2005, 9, 310-316.
17. Hajduk, P. J. Fragment-based drug design: how big is too big? J. Med. Chem. 2006, 49, 6972-6976.
18. Feher, M.; Schmidt, J. M. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comp. Sci. 2003, 43, 218-227.
19. McGaughey, G. B.; Gagne, M.; Rappe, A. K. Pi-stacking interactions: alive and well in proteins. J. Biol. Chem. 1998, 273, 15458-15463.
20. Dougherty, D. A. Cation-pi interactions in chemistry and biology: a new view of benzene, phe, tyr, and trp. Science 1996, 271, 163-168. (Pubitemid 26033294)
21. Ando, H. Y.; Radebaugh, G. W., Property-based drug design and preformulation. In Remington: The Science and Practice of Pharmacy; Lippincott, Williams and Witkins; Philadelphia, 2005; pp 720-744.
22. Delaney, J. S. ESOL: estimating aqueous solubility directly from molecular structure. J. Chem. Inf. Comp. Sci. 2004, 44, 1000-1005.
23. Lamanna, C.; Bellini, M.; Padova, A.; Westerberg, G.; Maccari, L. Straightforward recursive partitioning model for discarding insoluble compounds in the drug discovery process. J. Med. Chem. 2008, 51, 2891-2897.
24. Badertscher, M.; Bischofberger, K.; Munk, M. E.; Pretsch, E. A. Novel formalism to characterize the degree of unsaturation of organic molecules. J. Chem. Inf. Comp. Sci. 2001, 41, 889-893.
25. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 2003, 46, 1250-1256.
26. GVK Bio web site [online], http://www.gvkbio.com/Informatics.html/.
27. Some compounds did not have a publication date recorded and these were kept in the analysis: 28 phase 1, 50 phase 2 and 10 phase 3.
28. Pipeline Pilot is available from Accelrys, http://accelrys.com/products/ scitegic/.
29. JMP is available from http://www.jmp.com/.
30. Hou, T. J.; Xia, K.; Zhang, W.; Xu, X. J. ADME evaluation in drug discovery. 4. Prediction of aqueous solubility based on atom contribution approach. J. Chem. Inf. Comp. Sci. 2003, 44, 266-275.
31. Karthikeyan, M.; Glen, R. C.; Bender, A. General melting point prediction based on a diverse compound data set and artificial neural networks. J. Chem. Inf. Mod. 2005, 45, 581-590.
32. Yalkowsky, S. H.; Valvani, S. C. Solubility and partitioning I: Solubility of nonelectrolytes in water. J. Pharm. Sci. 1980, 69, 912-922.
33. Neera, J.; Samuel, H. Y. Estimation of the aqueous solubility I: Application to organic nonelectrolytes. J. Pharm. Sci. 2001, 90, 234-252.
34. Handbook of Chemistry and Physics, 72nd ed., CRC Press: Boca Raton, FL, 1991.
35. Chu, K. A.; Yalkowsky, S. H. An interesting relationship between drug absorption and melting point. Int. J. Pharm. 2009, 373, 24-40.
36. Thomas, V. H.; Bhattachar, S.; Hitchingham, L.; Zocharski, P.; Naath, M.; Surendran, N.; Stoner, C. L.; El-Kattan, A. The road map to oral bioavailability: an industrial perspective. Exp. Opin. Drug Metab. Tox. 2006, 2, 591-608.
37. Adam, F. L.; Gregory, C. F. Palladium-catalyzed coupling reactions of aryl chlorides. Angew. Chem., Int. Ed. 2002, 41, 4176-4211. (Pubitemid 35402094)
38. Shawn, D. W.; Timothy, E. B.; Joseph, R. M.; Stephen, L. B. A rationally designed universal catalyst for suzuki-miyaura coupling processes13. Angew. Chem., Int. Ed. 2004, 43, 1871-1876.
39. Huang, X.; Anderson, K. W.; Zim, D.; Jiang, L.; Klapars, A.; Buchwald, S. L. Expanding Pd-Catalyzed Bond-Forming Processes: The First Amidation of Aryl Sulfonates, Aqueous Amination, and Complementarity with Cu-Catalyzed Reactions. J. Am. Chem. Soc. 2003, 125, 6653-6655.
40. Yin, J.; Zhao, M. M.; Huffman, M. A.; McNamara, J. M. Pd-catalyzed N-arylation of heteroarylamines. Org. Lett. 2002, 4, 3481-3484.
41. Ritchie, T. J.; Macdonald, S. J. F. The impact of aromatic ring count on compound developability - are too many aromatic rings a liability in drug design. Drug Disc. Today 2009, doi:10.1016/j.drudis.2009.07.014.